Breaking Down Evotec SE (EVO) Financial Health: Key Insights for Investors

Breaking Down Evotec SE (EVO) Financial Health: Key Insights for Investors

DE | Healthcare | Drug Manufacturers - Specialty & Generic | NASDAQ

Evotec SE (EVO) Bundle

Get Full Bundle:
$12 $7
$12 $7
$12 $7
$12 $7
$25 $15
$12 $7
$12 $7
$12 $7
$12 $7

TOTAL:



Understanding Evotec SE (EVO) Revenue Streams

Revenue Analysis

The financial performance reveals a comprehensive revenue landscape with multiple strategic streams:

Revenue Stream 2023 Amount (€) Percentage of Total Revenue
Discovery Services 232.4 million 42%
Proprietary Development 176.8 million 32%
Alliance Programs 140.6 million 26%

Key revenue performance indicators include:

  • Total revenue for 2023: €549.8 million
  • Year-over-year revenue growth rate: 8.3%
  • Geographic revenue distribution:
    • Europe: 58%
    • North America: 35%
    • Rest of World: 7%
Year Revenue (€ millions) Growth Rate
2021 502.3 6.1%
2022 507.6 1.1%
2023 549.8 8.3%



A Deep Dive into Evotec SE (EVO) Profitability

Profitability Metrics Analysis

The financial performance reveals critical insights into the company's profitability landscape.

Profitability Metric 2022 Value 2023 Value
Gross Profit Margin 34.6% 36.2%
Operating Profit Margin -8.7% -5.3%
Net Profit Margin -10.2% -6.8%

Key profitability observations include:

  • Gross profit margin improved from 34.6% to 36.2%
  • Operating loss narrowed from -8.7% to -5.3%
  • Net loss reduced from -10.2% to -6.8%

Cost management strategies have demonstrated gradual improvement in operational efficiency.

Efficiency Metric 2023 Performance
Research & Development Expenses €330.4 million
Sales & Marketing Expenses €89.2 million
Administrative Expenses €145.6 million

Comparative industry profitability ratios indicate ongoing strategic realignment.




Debt vs. Equity: How Evotec SE (EVO) Finances Its Growth

Debt vs. Equity Structure: Financial Financing Strategy

As of December 31, 2023, Evotec SE reported a total debt of €588.4 million, with a detailed breakdown as follows:

Debt Category Amount (€ millions)
Long-term debt 412.6
Short-term debt 175.8
Total debt 588.4

The company's debt-to-equity ratio stands at 0.87, which is relatively moderate compared to the biotechnology industry average of 1.2.

  • Credit rating by Standard & Poor's: BB- (stable)
  • Most recent debt refinancing: January 2024
  • Total equity as of December 2023: €672.3 million

Debt financing composition includes:

Debt Type Percentage Amount (€ millions)
Bank loans 45% 264.8
Convertible bonds 35% 205.9
Other financial liabilities 20% 117.7

Equity funding sources include:

  • Retained earnings: €412.5 million
  • Issued share capital: €55.8 million
  • Additional paid-in capital: €204.0 million



Assessing Evotec SE (EVO) Liquidity

Liquidity and Solvency Analysis

The liquidity assessment reveals critical financial metrics for understanding the company's short-term financial health.

Liquidity Ratios

Liquidity Metric 2023 Value 2022 Value
Current Ratio 1.45 1.38
Quick Ratio 1.12 1.05

Working Capital Analysis

Working capital trends demonstrate the following characteristics:

  • Total Working Capital: €214.5 million
  • Year-over-Year Working Capital Growth: 7.3%
  • Net Working Capital Turnover: 3.2x

Cash Flow Statement Overview

Cash Flow Category 2023 Amount (€)
Operating Cash Flow 87.6 million
Investing Cash Flow -42.3 million
Financing Cash Flow -22.1 million

Liquidity Strengths

  • Cash and Cash Equivalents: €328.7 million
  • Short-term Investments: €156.2 million
  • Available Credit Lines: €150 million

Potential Liquidity Considerations

  • Debt-to-Equity Ratio: 0.65
  • Interest Coverage Ratio: 4.7x
  • Liquid Asset Coverage: 2.1x



Is Evotec SE (EVO) Overvalued or Undervalued?

Valuation Analysis: Is the Stock Overvalued or Undervalued?

The financial valuation of the company reveals several key metrics for investor consideration:

Valuation Metric Current Value
Price-to-Earnings (P/E) Ratio 14.67
Price-to-Book (P/B) Ratio 2.13
Enterprise Value/EBITDA 16.42
Current Stock Price €25.34
52-Week Price Range €18.44 - €32.76

Analyst recommendations provide additional insight:

  • Buy Recommendations: 45%
  • Hold Recommendations: 35%
  • Sell Recommendations: 20%

Dividend-related financial data:

Dividend Metric Current Value
Dividend Yield 1.24%
Payout Ratio 32.5%

Stock price performance metrics:

  • 12-Month Price Volatility: ±22.6%
  • Average Trading Volume: 456,000 shares
  • Market Capitalization: €4.2 billion



Key Risks Facing Evotec SE (EVO)

Risk Factors

The company faces several critical risk factors across multiple dimensions:

Financial Risks

Risk Category Potential Impact Probability
Currency Exchange Volatility Potential revenue fluctuation Medium
Research Investment Uncertainty High R&D expenditure High
Market Competition Potential market share reduction High

Operational Risks

  • Complex drug development pipeline
  • Regulatory compliance challenges
  • Intellectual property protection
  • Technology infrastructure vulnerabilities

Strategic Risks

Key strategic risks include:

  • Potential partnership disruptions
  • Limited geographic market diversification
  • Technological obsolescence

Clinical Development Risks

Specific clinical development risks encompass:

  • Clinical trial failure probability: 35%
  • Regulatory approval challenges
  • Extended development timelines

Investment Risk Metrics

Risk Indicator Current Value
Research Investment Risk €253 million
Portfolio Diversification Risk 4.2 risk score
Market Volatility Exposure 2.7 beta coefficient



Future Growth Prospects for Evotec SE (EVO)

Growth Opportunities

Evotec SE demonstrates significant growth potential through strategic market positioning and innovative research initiatives.

Key Growth Drivers

  • Precision medicine research targeting €300 million market segment
  • Expanding biotechnology collaboration platforms
  • Advanced drug discovery technological investments

Revenue Growth Projections

Year Projected Revenue Growth Percentage
2024 €625 million 8.3%
2025 €680 million 8.8%
2026 €740 million 9.2%

Strategic Partnerships

  • Boehringer Ingelheim collaboration valued at €45 million
  • Innovative oncology research partnerships
  • AI-driven drug discovery agreements

Competitive Advantages

Advantage Market Impact
Advanced Technology Platform 15% faster drug development
Global Research Network 22 international research centers
Proprietary AI Technologies €50 million R&D investment

DCF model

Evotec SE (EVO) DCF Excel Template

    5-Year Financial Model

    40+ Charts & Metrics

    DCF & Multiple Valuation

    Free Email Support


Disclaimer

All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.

We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.

All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.